Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed
cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with
concurrent stereotactic body radiation therapy (SBRT) and low dose radiotherapy (LDRT) in
treating patients with stage IV non-small cell lung cancer (NSCLC).
At least 39 participants will be enrolled in this study. All will take part at West China
Hospital, Sichuan University.